Literature DB >> 20668474

Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice.

M G Martin, J S Welch, G L Uy, T A Fehniger, S Kulkarni, E J Duncavage, M J Walter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20668474      PMCID： PMC3341627          DOI： 10.1038/leu.2010.156

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells.

Authors:  Daniella M Bahia Kerbauy; Vladimir Lesnikov; Beverly Torok-Storb; Eileen Bryant; H Joachim Deeg
Journal:  Blood       Date:  2004-10-01       Impact factor: 22.113

2.  NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors.

Authors:  Ana I Benito; Eileen Bryant; Michael R Loken; George E Sale; Richard A Nash; M John Gass; H Joachim Deeg
Journal:  Leuk Res       Date:  2003-05       Impact factor: 3.156

3.  Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.

Authors:  Leonard D Shultz; Bonnie L Lyons; Lisa M Burzenski; Bruce Gott; Xiaohua Chen; Stanley Chaleff; Malak Kotb; Stephen D Gillies; Marie King; Julie Mangada; Dale L Greiner; Rupert Handgretinger
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

4.  Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML.

Authors:  Yoriko Saito; Naoyuki Uchida; Satoshi Tanaka; Nahoko Suzuki; Mariko Tomizawa-Murasawa; Akiko Sone; Yuho Najima; Shinsuke Takagi; Yuki Aoki; Atsushi Wake; Shuichi Taniguchi; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Nat Biotechnol       Date:  2010-02-14       Impact factor: 54.908

5.  Engraftment of human myelodysplastic syndrome derived cell line in transgenic severe combined immunodeficient (TG-SCID) mice expressing human GM-CSF and IL-3.

Authors:  D K Kim; M Kojima; T Fukushima; M Miyasaka; H Nakauchi
Journal:  Eur J Haematol       Date:  1998-08       Impact factor: 2.997

6.  A robust xenotransplantation model for acute myeloid leukemia.

Authors:  P V Sanchez; R L Perry; J E Sarry; A E Perl; K Murphy; C R Swider; A Bagg; J K Choi; J A Biegel; G Danet-Desnoyers; M Carroll
Journal:  Leukemia       Date:  2009-07-23       Impact factor: 11.528

7.  Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice.

Authors:  L D Shultz; P A Schweitzer; S W Christianson; B Gott; I B Schweitzer; B Tennent; S McKenna; L Mobraaten; T V Rajan; D L Greiner
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

8.  Engraftment of NOD/SCID-beta2 microglobulin null mice with multilineage neoplastic cells from patients with myelodysplastic syndrome.

Authors:  Eleni Thanopoulou; Johanne Cashman; Theodora Kakagianne; Allen Eaves; Nicholas Zoumbos; Connie Eaves
Journal:  Blood       Date:  2004-02-12       Impact factor: 22.113
  8 in total
  12 in total

1.  NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Authors:  Emmanuel Griessinger; Michael Andreeff
Journal:  Haematologica       Date:  2018-06       Impact factor: 9.941

2.  Cytokine activation induces human memory-like NK cells.

Authors:  Rizwan Romee; Stephanie E Schneider; Jeffrey W Leong; Julie M Chase; Catherine R Keppel; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Blood       Date:  2012-09-14       Impact factor: 22.113

Review 3.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

4.  OKT3 prevents xenogeneic GVHD and allows reliable xenograft initiation from unfractionated human hematopoietic tissues.

Authors:  Mark Wunderlich; Ryan A Brooks; Rushi Panchal; Garrett W Rhyasen; Gwenn Danet-Desnoyers; James C Mulloy
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

5.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Authors:  Garrett W Rhyasen; Lyndsey Bolanos; Jing Fang; Andres Jerez; Mark Wunderlich; Carmela Rigolino; Lesley Mathews; Marc Ferrer; Noel Southall; Rajarshi Guha; Jonathan Keller; Craig Thomas; Levi J Beverly; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; Jaroslaw P Maciejewski; James C Mulloy; Daniel T Starczynowski
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743

Review 6.  Myelodysplasia is in the niche: novel concepts and emerging therapies.

Authors:  E Bulycheva; M Rauner; H Medyouf; I Theurl; M Bornhäuser; L C Hofbauer; U Platzbecker
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 7.  Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.

Authors:  Domenico Mattiucci; Giulia Maurizi; Pietro Leoni; Antonella Poloni
Journal:  Cell Transplant       Date:  2018-04-23       Impact factor: 4.064

8.  Myelodysplastic syndrome patient-derived xenografts: from no options to many.

Authors:  Christophe Côme; Alexander Balhuizen; Dominique Bonnet; Bo T Porse
Journal:  Haematologica       Date:  2020-03-19       Impact factor: 9.941

9.  In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice.

Authors:  Malte von Bonin; Martin Wermke; Kadriye Nehir Cosgun; Christian Thiede; Martin Bornhauser; Gerard Wagemaker; Claudia Waskow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

10.  A highly efficient and faithful MDS patient-derived xenotransplantation model for pre-clinical studies.

Authors:  Yuanbin Song; Anthony Rongvaux; Ashley Taylor; Tingting Jiang; Toma Tebaldi; Kunthavai Balasubramanian; Arun Bagale; Yunus Kasim Terzi; Rana Gbyli; Xiaman Wang; Xiaoying Fu; Yimeng Gao; Jun Zhao; Nikolai Podoltsev; Mina Xu; Natalia Neparidze; Ellice Wong; Richard Torres; Emanuela M Bruscia; Yuval Kluger; Markus G Manz; Richard A Flavell; Stephanie Halene
Journal:  Nat Commun       Date:  2019-01-21       Impact factor: 14.919
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.